Petitions were filed by pharma companies and an association of medicine manufacturing firms challenging the government’s new drug pricing order that asked them to slash prices of 348 medicines The Delhi High Court has t
She received the Padma Shri Award in 2007 from Government of India Cipla has announced the appointment of Naina Lal Kidwai as an independent director on its board effective November 6, 2015. Until recently Kidwai was Executiv
Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant Ltd for a consideration of USD 25,775,000 to focus on biological segment under its arm Cipla BioTec.
Divests its remaining stake in Hong Kong-based Biomab Holding to focus on global development under Cipla BioTec Cipla has entered into a definitive agreement to sell its entire 25 per cent stake in Biomab Holding Limited, Hon
As many as nine issues have been raised by the regulator under ‘Form 483’ regarding manufacturing practices in the plant Cipla’s Indore plant has come under the scanner of US health regulator for manufacturi
Regulators want to make it easier for law enforcement agencies to track cough syrup abuse in the country and bottles smuggled to neighbouring Bangladesh, where it was banned in the 1980s but is still sought by addicts.
Cipla acquires two generics businesses in the US: Cipla has announced it is acquiring two privately held generic pharma businesses, InvaGen and Exelan Pharma, in the US for a transaction value (TV) of $550m.
With a view to enhance its presence in the world's largest generics market, Cipla on Friday said it would acquire 100% of generic businesses of two pharmaceutical companies in the US for $550 million in a cash deal.
Cipla stocks will be in focus today as the the Indian generic drugmaker on Friday informed BSE that its UK arm, Cipla EU, has entered into definitive agreements to acquire two US-based companies InvaGen Pharmaceuticals Inc an
Indian generic drugmaker Cipla on Friday informed the Bombay Stock Exchane that its UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuti
Signs agreements to acquire 100 per cent of generic businesses in the US for $550 million Cipla’s UK arm, Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals and Ex
Vohra will be the global chief financial and strategy officer and Jha will take over as global chief people officer Cipla has appointed Umang Vohra as global chief financial and strategy officer and Prabir Jha as global chief
Profit after tax grew by 120.9 per cent to Rs 651 crore, up from Rs 295 crore Cipla has announced its unaudited consolidated financial results for the quarter ended June 30, 2015. Income from operations grew by 41.6 per cent